TRIM29 upregulation contributes to chemoresistance in triple negative breast cancer via modulating S100P-β-catenin

Qitong Wu1, Sumit Siddharth2, Deepak Verma1

  • 1Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, 1650 Orleans Street, CRB 1, Rm 145, Baltimore, MD, 21231, USA.

Insights

Triple negative breast cancer (TNBC) chemoresistance involves TRIM29, which promotes aggressive cell behavior and resistance. Targeting TRIM29, S100P, and β-catenin pathways offers new therapeutic strategies for TNBC.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Triple negative breast cancer (TNBC) presents limited therapeutic options and significant chemotherapy resistance.
  • Identifying key molecular drivers of chemoresistance is crucial for developing effective treatments.

Purpose of the Study:

  • To investigate the role of TRIM29 in TNBC chemoresistance.
  • To elucidate the molecular mechanisms and signaling pathways involved in TRIM29-mediated chemoresistance.

Main Methods:

  • Differential gene expression analysis in recurrent TNBC.
  • TRIM29 expression modulation (overexpression and knockout) in TNBC cells.
  • RNA-sequencing to identify downstream genes and pathways.
  • Inhibitor studies targeting S100P and β-catenin pathways.

Main Results:

  • TRIM29 is highly expressed in chemoresistant TNBC and its modulation affects chemosensitivity and tumor growth.
  • TRIM29 knockout increases chemosensitivity and reduces TNBC tumor growth.
  • TRIM29 regulates a network of genes including S100P, SERPINB3/4, CEACAM5/6, and CDH6, and influences the β-catenin pathway.
  • S100P and β-catenin inhibition synergistically impacts chemoresistant TNBC growth and survival.

Conclusions:

  • TRIM29 is a critical regulator of chemoresistance in TNBC, promoting aggressive phenotypes.
  • The TRIM29-S100P-β-catenin axis represents a promising therapeutic target for overcoming TNBC chemoresistance.

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR...
2.2K